Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Genmab Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Genmab kazanç ve gelirin sırasıyla yıllık 20% ve 14.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 17.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 16.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

19.4%

Kazanç büyüme oranı

17.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.9%
Gelir büyüme oranı	14.4%
Gelecekteki özkaynak getirisi	16.5%
Analist kapsamı	Good
Son güncelleme	16 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:GMAB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (DKK Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	28,767	7,606	7,467	8,070	18
12/31/2025	24,484	6,255	6,124	6,893	24
12/31/2024	20,836	5,418	2,036	5,664	25
6/30/2024	19,016	5,540	6,515	6,735	N/A
3/31/2024	17,783	5,467	5,358	5,658	N/A
12/31/2023	16,474	4,352	7,004	7,380	N/A
9/30/2023	16,884	4,188	5,687	6,106	N/A
6/30/2023	16,227	4,641	5,634	6,037	N/A
3/31/2023	15,220	5,197	6,196	6,560	N/A
12/31/2022	14,505	5,452	3,595	3,912	N/A
9/30/2022	11,987	5,654	3,480	3,755	N/A
6/30/2022	10,210	3,962	1,964	2,234	N/A
3/31/2022	9,020	2,377	1,349	1,630	N/A
12/31/2021	8,417	2,957	1,976	2,228	N/A
9/30/2021	7,907	2,873	947	1,189	N/A
6/30/2021	7,321	2,513	5,609	5,820	N/A
3/31/2021	10,800	5,585	5,427	5,704	N/A
12/31/2020	10,111	4,758	6,126	6,433	N/A
9/30/2020	11,028	5,649	7,128	7,406	N/A
6/30/2020	10,344	5,656	2,369	2,647	N/A
3/31/2020	5,667	2,363	2,444	2,592	N/A
12/31/2019	5,366	2,166	1,215	1,326	N/A
9/30/2019	3,641	1,528	1,252	1,355	N/A
6/30/2019	3,199	1,170	782	1,248	N/A
3/31/2019	2,935	1,345	729	1,199	N/A
12/31/2018	3,025	1,472	537	1,015	N/A
9/30/2018	2,807	1,424	583	1,062	N/A
6/30/2018	2,532	1,239	796	892	N/A
3/31/2018	2,796	1,286	N/A	1,301	N/A
12/31/2017	2,365	1,104	N/A	1,589	N/A
9/30/2017	2,275	1,159	N/A	1,260	N/A
6/30/2017	2,316	1,354	N/A	1,422	N/A
3/31/2017	1,897	1,215	N/A	1,088	N/A
12/31/2016	1,816	1,187	N/A	328	N/A
9/30/2016	1,463	735	N/A	658	N/A
6/30/2016	1,376	686	N/A	591	N/A
3/31/2016	1,196	535	N/A	358	N/A
12/31/2015	1,133	764	N/A	311	N/A
9/30/2015	774	443	N/A	70	N/A
6/30/2015	768	463	N/A	23	N/A
3/31/2015	710	420	N/A	98	N/A
12/31/2014	850	301	N/A	133	N/A
9/30/2014	851	292	N/A	110	N/A
6/30/2014	729	138	N/A	-31	N/A
3/31/2014	751	138	N/A	-108	N/A
12/31/2013	664	70	N/A	-128	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: GMAB 'nin tahmini kazanç büyümesi (yıllık 20% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: GMAB şirketinin kazançlarının (yıllık 20% ) US pazarından (yıllık 15.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: GMAB şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: GMAB şirketinin gelirinin (yıllık 14.1% ) US pazarından (yıllık 8.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: GMAB şirketinin gelirinin (yıllık 14.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: GMAB 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 16.5 %).

Genmab Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Provides Earnings Guidance for 2023

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Revises Earnings Guidance for 2022

Recent updates

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Genmab: A Complicated Tale

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab Acquires A Missing Piece For Its Pipeline

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab: Recent Updates Support The Growth Narrative

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab improves FY 2022 guidance

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab: A Royalty Powerhouse With A Strong Pipeline

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab: Looking For Growth At A Reasonable Price

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab: A Biotech Company On The Rise

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab: Ready For More Growth In 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

U.S. Food and Drug Administration Grants Approval to TIVDAK

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin